Prostate Cancer

A new study has confirmed that a genetic test that measures cell cycle progression (CCP) can be a useful tool for predicting which patients will have prostate cancer recurrence, especially when combined with existing information from laboratory and pathology tests.

The FDA has approved radium Ra 223 dichloride (Xofigo) injection for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease.

Older prostate cancer patients with three or more underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by UCLA urologists.

The AUA and the American Society for Radiation Oncology (ASTRO) have released a joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence.

A new genomic test for prostate cancer appears to help predict whether men are more likely to harbor an aggressive form of the disease, report researchers from the University of California, San Francisco.

New evidence from the European Randomized Study of Screening for Prostate Cancer (ERSPC) suggests that prostate cancer screening is beneficial, particularly in the core age group of 55 to 69 years.

Robot-assisted laparoscopic prostatectomy in patients with intermediate- or high-risk cancers achieves outcomes similar to those attained by the open procedure, results of a large retrospective comparative study indicate.

Following the rollout of several new treatments for metastatic, castration-resistant prostate cancer (mCRPC), a new AUA clinical guideline is aimed at assisting in clinical decision making.

Prostate cancer patients who also have long-term diabetes mellitus and/or diabetes with organ failure may have a higher likelihood of developing more aggressive, poorly differentiated disease, new study data suggest.

The most recent data from the COU-AA-302 phase III trial support the efficacy and safety of abiraterone acetate (Zytiga) as a treatment for metastatic castration-resistant prostate cancer in men who are chemotherapy-naive.

The AUA has released a PSA-focused, evidence-based guideline on early detection of prostate cancer that is intended to assist the urologist in advising an average-risk, asymptomatic man about prostate cancer screening, said H. Ballentine Carter, MD.

Drugs and devices in the pipeline from Medivation, Inc.; Astellas Pharma Inc.; TARIS Biomedical; Exelixis, Inc.; and Bioniche Life Sciences Inc.

A new closer look at genomes in prostate cancer has revealed that genetic mutations occur in abrupt, periodic bursts, causing complex, large-scale reshuffling of DNA driving the development of the disease.

Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with nonobese men and were at a greater risk for subsequently developing prostate cancer, a recently published study found.

Incidence rates for prostate and other cancers are statistically higher than expected among World Trade Center rescue and recovery workers, according to a recent study.

Prostate cancer patients who also have long-term diabetes mellitus and/or diabetes with organ failure may have a higher likelihood of developing more aggressive, poorly differentiated prostate cancer, a new study suggests.

Researchers have shown, via a phase I trial, that the relationship between nerves and prostate cancer in perineural invasion is susceptible to therapeutic intervention with neurotoxic agents such as onabotulinumtoxinA (Botox).

Transrectal anterior zone sampling of the prostate may be a viable alternative to transperineal template biopsies in patients with negative previous biopsies and with rising PSA or persistently elevated PSA, researchers from the United Kingdom report.

African-American men eligible for active surveillance have a higher risk of advanced cancer on final surgical pathology compared to Caucasian men, suggesting the need for more stringent criteria for active surveillance for African-American men, according to a recently published study.

A single PSA test at 45 years of age may help predict long-term risk of developing aggressive prostate cancer, according to a recent study.

EDAP TMS said the FDA has provided a positive filing review notification on the company’s pre-market approval application for its Ablatherm Integrated Imaging HIFU (high-intensity focused ultrasound) device for the treatment of low-risk, localized prostate cancer.

New evidence from the second-largest section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) suggests that prostate cancer screening is beneficial, particularly in the core age group of 55 to 69 years.

Men with abnormal findings on digital rectal exam or other indicators of prostate cancer should be tested, but the evidence is insufficient to justify preferentially screening diabetic men because they may be at a higher risk of developing clinically significant prostate cancer.

New research on the downstream outcomes following PSA screening may help inform individualized decisions among older men considering screening.

Intermittent androgen deprivation therapy (ADT) may compromise survival for metastatic hormone-sensitive prostate cancer patients compared with continuous ADT, according to a recently published multicenter study.